Walgreens Boots Alliance (NASDAQ:W(BA)) is set to announce its earnings results before the market opens on Thursday, January 7th. Analysts expect Walgreens Boots Alliance to post earnings of $1.03 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Walgreens Boots Alliance (NASDAQ:W(BA)) last released its earnings results on Thursday, October 15th. The pharmacy operator reported $1.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.06. The firm had revenue of $34.75 billion for the quarter, compared to the consensus estimate of $34.36 billion. Walgreens Boots Alliance had a net margin of 0.33% and a return on equity of 18.33%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.43 EPS. On average, analysts expect Walgreens Boots Alliance to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.
NASDAQ:W(BA) opened at $39.34 on Thursday. The firm’s 50-day moving average price is $40.42 and its 200-day moving average price is $39.27. The company has a market capitalization of $33.99 billion, a PE ratio of 78.68, a P/E/G ratio of 1.52 and a beta of 0.44. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.67 and a quick ratio of 0.32. Walgreens Boots Alliance has a 1-year low of $33.36 and a 1-year high of $59.78.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 11th. Stockholders of record on Thursday, November 19th were given a $0.4675 dividend. This represents a $1.87 dividend on an annualized basis and a dividend yield of 4.75%. The ex-dividend date was Wednesday, November 18th. Walgreens Boots Alliance’s dividend payout ratio is presently 39.45%.
A number of equities analysts recently weighed in on W(BA) shares. The Goldman Sachs Group decreased their price objective on shares of Walgreens Boots Alliance from $37.00 to $33.00 and set a “sell” rating for the company in a report on Tuesday, October 6th. Morgan Stanley reduced their target price on Walgreens Boots Alliance from $45.00 to $40.00 and set an “equal weight” rating for the company in a report on Thursday, September 3rd. Bank of America reissued a “sell” rating and issued a $37.00 target price on shares of Walgreens Boots Alliance in a report on Wednesday, October 7th. TheStreet raised Walgreens Boots Alliance from a “c+” rating to a “b-” rating in a report on Wednesday, December 9th. Finally, Royal Bank of Canada reduced their target price on Walgreens Boots Alliance from $45.00 to $38.00 and set a “sector perform” rating for the company in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the company’s stock. Walgreens Boots Alliance currently has an average rating of “Hold” and an average target price of $40.86.
In related news, CAO Marco Patrick Anthony Pagni sold 5,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $41.55, for a total transaction of $207,750.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 16.91% of the company’s stock.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores.
Recommended Story: What is the NASDAQ?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]